Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
126.28(c) 126.37(c) 124.34(c) 121.74(c) 121.19(c) Last
682 527 590 162 1 284 419 1 007 403 954 274 Volume
+1.76% +0.07% -1.61% -2.09% -0.45% Change
More quotes
Financials ($)
Sales 2017 1 468 M
EBIT 2017 -71,1 M
Net income 2017 -168 M
Finance 2017 340 M
Yield 2017 -
Sales 2018 1 667 M
EBIT 2018 123 M
Net income 2018 102 M
Finance 2018 743 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 299,53
EV / Sales2017 16,7x
EV / Sales2018 14,5x
Capitalization 24 929 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology.Its product, Jakafi, a JAK1 and JAK2 inhibitor, is... 
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
08/17 INCYTE : Forbes Magazine Names Incyte One of the World's Most Innovative Compani..
08/16 INCYTE : Scientist Behind Incyte's Jakafi Ready to Strike Big in Delaware Again
08/15 INCYTE : founder gets $474K from Delaware to fund new cancer drug company Prelud..
08/10 INCYTE : Forbes Magazine Names Incyte One of the World’s Most Innovative C..
08/09 Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recen..
08/08 INSIDER TRADING ACTIVITY INCYTE CORP : INCY) – Insider Sold 3,000 shares o..
08/03 INCYTE : New Pharmacokinetics Data Have Been Reported by Investigators at Incyte..
08/03 ELI LILLY AND : Lilly and Incyte Provide Update on Baricitinib
08/02 INCYTE : posts loss for quarter, but sees strong sales for blockbuster drug Jaka..
08/01 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
More news
Sector news : Biotechnology & Medical Research - NEC
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02:17aSomewhat Positive News Coverage Somewhat Unlikely to Impact Merus N.V. $MRUS .. 
08/19Gilead: Road To $100  
08/18Incyte Corporation 2017 Q2 - Results - Earnings Call Slides  
08/17Merus B.V. (MRUS) Presents At Wedbush PacGrow Healthcare Conference - Slidesh.. 
08/17State of Wisconsin Investment Board Has $30.04 Million Stake in Incyte Corpor.. 
More tweets
Qtime:64
News from SeekingAlpha
08/18 Incyte Corporation 2017 Q2 - Results - Earnings Call Slides
08/17 Evercore ISI initiates 14 bullish calls, 9 neutral
08/08 AGIOS : Smooth First Mover In Cancer Metabolism
08/07 Vanguard Brings You Healthy Returns With Less Volatility
08/02 ABBVIE, PART 2 : Its Strengths Beyond Humira, And Weakness
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 148 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION20.86%24 929
QUINTILES IMS HOLDINGS INC20.38%19 823
LONZA GROUP42.86%17 682
CELLTRION, INC.--.--%11 804
ALKERMES PLC-8.38%7 821
ALNYLAM PHARMACEUTICALS, INC.114.42%7 469